Pfizer Inc.
NYSEPfizer heads into its August 4 earnings event carrying an unusual distinction: short sellers rebuilt aggressively after the July 28 beat, and that positioning has barely softened in the days since. Short interest tells the most interesting story heading into this print. After spiking 27% in the week through July 28 — as documented in the prior ORTEX note — SI has stabilised near…
PFE short interest jumps 26.8% in one week to 3.24% of float, driven by 184M shares short as of July 28.
A new long-form analysis for PFE this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumPfizer heads into its August 4 earnings event carrying an unusual distinction: short sellers rebuilt aggressively after the July 28 beat, and that positioning has barely softened in the days since. Short interest tells…
Snapshot as of 6 Aug 2026
Pfizer delivered its Q2 print on July 28 and the stock rose — yet short sellers added positions aggressively in the same week, creating the week's defining tension. The short interest story is the standout here. SI…
Pfizer heads into its July 28 earnings report with the Street in a quiet retreat — analysts cutting targets but holding ratings, while positioning data shows no particular stress in either direction. The most telling…
PFE heads into its July 28 earnings with shorts continuing to unwind, the Street growing more defensive, and the stock stuck near multi-year lows — a combination that makes the next few weeks more about fundamental…
PFE enters July with a notable reversal in the short-selling story — bears have pulled back sharply over the past week, yet the stock has continued sliding, closing at $24.08 after an 8% drop over the past month. The…
PFE heads into its July 28 earnings report with short sellers adding positions at the fastest pace in months, even as the stock drops to its lowest levels of the year. Short interest is the standout story this week.…
Pfizer enters the week with a curious split: the stock is quietly grinding higher, up 0.6% on the week to $25.70, yet short sellers have been adding positions at their fastest monthly pace in months. Short interest is…
Pfizer enters the final stretch of May with short interest still rebuilding from its April lows, options traders remaining cautious, and a divided analyst community that nonetheless prices in meaningful recovery from a…
Pfizer heads into the back half of May with short interest at its highest level in six weeks, options sentiment tilting more defensive, and the Street divided on where the stock goes from a post-earnings $25.87. The…
Pfizer delivered a Q1 beat but the stock ended the week almost flat — and short sellers spent the week adding to positions at a pace that has been building steadily since early April. Short interest is the story that…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PFE — free to start on ORTEX.
Sign up for free →Open PFE on ORTEX